Recent news on Xibrom

Ista’s Setback Puts More Pressure on Flagship Xibrom  -  May 13, 2007
Orange County Business Journal,The situation, according to Murphy, places “material pressure� on a once-daily dosage of Ista’s Xibrom drug, which treats pain after cataract surgery.

ISTA Pharmaceuticals Reports First Quarter 2007 Financial Results  -  26 Apr 2007
PR Newswire (press release),In addition, during the first quarter of 2007, ISTA reported positive and statistically significant results from its Xibrom once-daily Phase III clinical

ISTA Pharmaceuticals Reports 2006 Financial Results  -  Mar 26, 2007
Drug Newswire (press release),..."Finally, ISTA's sales and marketing team worked extremely hard this year to gain market share for both Xibrom and Istalol, and in the fourth quarter,

ISTA posts net loss of $38.4 million for 2006  -  Mar 7, 2007
OSN SuperSite (subscription),Net sales increased more than 200% for Xibrom (bromfenac ophthalmic solution 0.09%) and Istalol (timolol maleate 0.5%), rising to $20.2 million and $8.3

The Cost of Clinical Trials  -  Mar 20, 2007
Drug Discovery & Development,Johns Hopkins University announces plans to study the effects of several ocular drugs (Bromfenac, also called Xibrom; Nepafenac, also called Nevanac;

ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM ...  -  Feb 9, 2007
PipelineReview.com (press release),Announced highly statistically significant results from its initial analysis of the Company's US Phase III clinical trials of Xibrom(TM) (bromfenac sodium

ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM ...  -  Feb 9, 2007
Medical News Today (press release),The multi-center studies evaluated Xibrom once-daily formulation versus placebo in over 500 patients who underwent cataract surgery.

UPDATE 2-ISTA Pharma shares rise on Xibrom positive results  -  Feb 8, 2007
ReutersO: Quote, Profile , Research) reported positive preliminary results from a late stage clinical study of its post-cataract pain relief treatment Xibrom,

UPDATE 1-Ista Pharma says Xibrom study shows positive results  -  Feb 8, 2007
ReutersO: Quote, Profile , Research) said late-stage trials for the once-daily formulation of its drug Xibrom was statistically significant in treating

ISTA Sees Positive Xibrom Results  -  Feb 8, 2007
Forbes,...on Thursday reported positive preliminary data from a late stage study of its post-cataract surgery treatment Xibrom, sending its shares sharply higher.

ISTA Pharmaceuticals Inc. Rebounds Following News On Clinical ...  -  Feb 8, 2007
Trading Markets,...revealed statistically significant results from its initial analysis of the company's US Phase III clinical trials of Xibrom once-daily formulation.

Pharma Sector: Few Newsmakers Of The Week - Opexa, J&J, Glaxo ...  -  Feb 11, 2007
Trading Markets,Over 500 patients who underwent cataract surgery were enrolled in the trial, which compared Xibrom once-daily formulation with placebo.

Biotech Day In Review: Accuray Had Spectacular IPO  -  Feb 8, 2007
Seeking Alpha,ISTA Pharma (ISTA) released positive data from a Phase III trial of Xibrom, a once daily treatment for ocular pain and inflammation in cataract surgery

Thursday's Small-Cap Winners & Losers  -  Feb 8, 2007
TheStreet.comIsta Pharmaceuticals (ISTA - Cramer's Take - Stockpickr) announced that an advanced-phase study of a once-daily version of its Xibrom product, which treats

StreetInsider.com Pre-Open Movers 02/08  -  Feb 8, 2007
StreetInsider.com (subscription),...from its initial analysis of the Company's US Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) once-daily formulation.

(PRN) - Webcast Alert: MGP Ingredients, Inc. Announces Second ...  -  Feb 8, 2007
Bolsamania.com,...(PRN) - ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From US Phase III Trials ... [+]

An eye for innovation  -  Dec 14, 2006
OCRegister,2008– A new formulation of Xibrom for inflammation from eye allergies or Xibrom Once Daily for pain relief in inflamed eyes after cataract surgery.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional